Capricor Therapeutics (NASDAQ:CAPR) Cut to “Neutral” at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a buy rating to a neutral rating in a research note released on Thursday, MarketBeat.com reports.

A number of other brokerages have also commented on CAPR. HC Wainwright reissued a “neutral” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Piper Sandler lowered shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 target price on the stock. in a report on Thursday. Alliance Global Partners cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a research report on Tuesday, July 28th. Oppenheimer reaffirmed a “market perform” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Finally, B. Riley Financial cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a research note on Monday, July 27th. Ten equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of “Reduce” and a consensus price target of $29.15.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $3.85 on Thursday. Capricor Therapeutics has a one year low of $2.96 and a one year high of $40.37. The company has a market cap of $222.95 million, a price-to-earnings ratio of -1.66 and a beta of 0.42. The firm has a 50 day simple moving average of $23.00 and a 200 day simple moving average of $26.77.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, analysts expect that Capricor Therapeutics will post -1.62 EPS for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 25,000 shares of company stock valued at $759,158 over the last quarter. 9.20% of the stock is currently owned by insiders.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently modified their holdings of CAPR. Russell Investments Group Ltd. lifted its position in shares of Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the period. ACT Capital Management LLC acquired a new stake in Capricor Therapeutics in the fourth quarter worth $43,000. KBC Group NV acquired a new stake in Capricor Therapeutics in the first quarter worth $44,000. Tower Research Capital LLC TRC increased its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares in the last quarter. Finally, Regal Investment Advisors LLC bought a new stake in Capricor Therapeutics in the third quarter valued at $92,000. Institutional investors own 21.68% of the company’s stock.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Neutral Sentiment: The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support Deramiocel’s effectiveness. The vote is non-binding, so the FDA could still reach a different decision, but it is a significant setback for Capricor’s regulatory path. Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
• Neutral Sentiment: FDA briefing materials and media reports questioned whether Deramiocel met its pre-specified cardiac endpoint and challenged Capricor’s interpretation of Phase 3 results. The dispute centers on changes to the statistical analysis plan that allegedly were not agreed to by the FDA before the company resubmitted its biologics license application. Capricor plummets after FDA panel votes against Duchenne heart disease therapy
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations or filed shareholder class actions alleging that Capricor made materially misleading statements or failed to disclose regulatory and clinical-data risks related to Deramiocel. The lawsuits add legal, financial and reputational risk, although the allegations have not been proven. Investors have been encouraged to contact the firms, with some notices citing a September 28, 2026 deadline. CAPR Investor Alert: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics Investors
• Negative Sentiment: Analysts responded by cutting ratings, including downgrades from Cantor Fitzgerald, Maxim Group, Ladenburg Thalmann and Alliance Global Partners. Cantor moved to Neutral with a $3.50 price target, while JonesTrading reaffirmed a Hold rating. Capricor Therapeutics downgraded by Cantor Fitzgerald

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.